The Germany-based global pharmaceutical company Boehringer Ingelheim recently announced the establishment of a research alliance with the Harvard Stem Cell Institute (HSCI) to discover new targets for treating fibrotic diseases, such as chronic kidney disease (CKD), nonalcoholic steatohepatitis (NASH), and idiopathic pulmonary fibrosis (IPF). The collaborative project, called Harvard Fibrosis Network, is…
Fibrotic Disease Therapy Research Collaboration Established Between Boehringer Ingelheim, Harvard Scientists
5 Celebrities Who Have Lost Loved Ones to PF
1. Aoife Clancy Musician Aoife Clancy was famous for being a member of the band Cherish the Ladies. On September 6th, 2002, she lost her father to pulmonary fibrosis after a three-year struggle with the disease. Aoife and Bobby Clancy had a close relationship as he was the one that…
New York City-based Kadmon Corp., a biopharma focused on developing therapies for significant unmet medical needs, recently announced the start of the first dosing regimen in a patient in its Phase 2 clinical trial assessing the drug KD025, the company’s rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment of idiopathic pulmonary fibrosis…
Boehringer Ingelheim, Inventiva Collaborate to Find New Idiopathic Pulmonary Fibrosis Treatments
Germany based Boehringer Ingelheim and France based Inventiva have announced a new multi-year research and drug discovery collaboration and licensing agreement. Under the agreement, Inventiva and Boehringer Ingelheim teams will work on validation of a new therapeutic concept to discover new medicines for treating idiopathic pulmonary fibrosis (IPF) and other…
A recent study from Korea indicates that sublobar resection is less likely to result in death compared to a lobar resection for lung cancer patients with idiopathic pulmonary fibrosis. The research report, “Clinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with…
Boehringer Ingelheim and Inventiva recently signed a new multi-year drug discovery and research partnership and licensing agreement. Research teams from both companies will jointly work to validate a new therapeutic concept with the purpose of finding novel therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. The…
Could COPD and Pulmonary Fibrosis be Related?
There are many shared risk factors for the development of the lung diseases pulmonary fibrosis (PF) and chronic obstructive pulmonary disease (COPD), but researchers of the two chronic conditions usually focus on understanding each disease separately. New research has found evidence that there may be a common genetic predisposition for the development of…
18 Celebrities Diagnosed with Pulmonary Fibrosis
1. Bill Bright William R. Bright, best known as Bill Bright, is the co-founder of the largest Christian ministry in the world, the Campus Crusade for Christ. In 2003, he died from complications related to pulmonary fibrosis, as announced on his website. 2. Boyd Bennett The…
Beating Pulmonary Fibrosis: Hamish Osborne Story
In this video from schoolofmedicine, meet Hamish S. Osborne and Christine C. Osborne. Mr. Osborne was diagnosed with IPF and had go to through surgery for a double-lung transplant. After that procedure, the couple became parte of the founding supporters of the Program in Lung Healing.
PFF Care Center Network: What You Need to Know
PFF Care Center Network is a group of medical centers which dedicate their work to improving the lives of those living with pulmonary fibrosis. According to the Pulmonary Fibrosis Foundation, these kinds of centers are expanding and keep growing. Their main purpose is to treat patients with fibrotic lung…
Your PF Community
Recommended Posts
- With FDA hold lifted, IPF clinical trial of LTI-03 begins dosing patients
- How we manage the long commute to my IPF doctor appointments
- In preparing for emergencies, we’re using technology to our advantage
- US, EU regulators name deupirfenidone an orphan drug for treating IPF
- This month is our time to raise awareness about rare diseases
